Korea FDA Withdraws Abbott's Meridia; Criticism Increases On Agency's Dependence On U.S. FDA For Safety
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea FDA banned new prescriptions for Abbott's obesity product sibutramine while it recommended "voluntary withdrawal" of the product following similar actions in the U.S. and Europe, drawing criticism that KFDA is too reliant on foreign agencies for monitoring drug safety
You may also be interested in...
In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications
In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications
In Replay Of Avandia Ban, Saudi Arabia Is First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
Country's Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long-acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications.